Melbourne Clinical Trials

The Inhibitor Study

The purpose of the study is to investigate a potential new treatment for complement mediated diseases.

9 + 2 x 1 + 5 nights
7 + 2 vaccine visits

The complement system is a part of the immune system. When this malfunctions, it can cause autoimmune diseases. Diseases related to the regulation of the complement system include autoimmune diseases such as lupus (an inflammatory disease caused when the immune system attacks its own tissues) and rheumatoid arthritis (joint inflammation and pain).

There are already several similar treatments that block specific elements of the complement system to treat these diseases, but there is an ongoing need for new & improved treatments.

The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.

Study Duration:
• 2 sets of Vaccine visits
• 9-night inpatient stay
• 2 sets of 1-night inpatient stays
• 5 night inpatient stay
• 7 outpatient visits


Biological Sex Healthy males and females
Age 18 - 55 years old
BMI 18 - 32kg/m²
Medical History No significant medical history
Medications Not taking any medication
Smoking History Non-smokers or smokers who smoke less than 10 per week